Date: 2011-12-07
Type of information: R&D agreement
Compound: diagnostic biomarkers in endometriosis
Company: Protagen (Germany) Bayer HealthCare (Germany)
Therapeutic area: Gynecology - Women's health
Type agreement: R&D
Action mechanism:
Disease: endometriosis
Details: Protagen and Bayer HealthCare Pharmaceuticals have started a new collaboration project for the clinical validation of diagnostic biomarkers in Endometriosis. This new cooperation project builds on the results of the Endometriosis biomarker discovery study performed last year, and is already the third UNIarray® Project within the collaboration between the two partners in the last three years. Aim of the current study is to employ the UNIarray® technology (technology platform for the development of novel serum based diagnostics) for the predictive diagnosis of Endometriosis and to improve patient’s quality of life.
Financial terms:
Latest news:
